PPARδ activators are in development for the treatment of dyslipidemia,obesity and/or insulin resistance in patients with the metabolic syndrome [78].PPARδ agonists have advantageous effects in obesity prevention and modulationof lipoprotein metabolism [54, 57, 58]. Here, PPARD is linked to obesity due to melanocortin 4 receptor deficiency.